Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | PNH treatment: ravulizumab vs. eculizumab

Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, Leeds Teaching Hospital NHS Trust, Leeds, UK, discusses patient preferences for the treatment of their paroxysmal nocturnal hemoglobinuria (PNH). Dr Hill specifically mentions the results of a patient survey of ravulizumab (alxn1210) and eculizumab. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.